TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15552635
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of 1000 mg extended-release divalproex sodium
Study: 11518478
Drug: Li 1370
Normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Li 1370 (240 mg)
Study: 29366988
Drug: RG7652 (PCSK9
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 (PCSK9 inhibiting antibody)
Study: 24438596
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (0.2%) application
Study: 20490383
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 3)
Study: 20490383
Drug: Declined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Declined treatment (group 2)
Study: 14980948
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine + 1 mL isotonic saline
Study: 11601114
Drug: Bone grafting
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone grafting and substitutes (biologically inert, osteoconductive, or osteoinductive) and osteoinductive growth factors and hormones as supplements to treatment.
Study: 9834259
Drug: Additional omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional omeprazole, 20 mg at bedtime
Study: 9834259
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg at bedtime
Study: 9834259
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg at bedtime
Study: 7930273
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (1) streptokinase with intravenous heparin; (2) streptokinase with subcutaneous heparin; (3) accelerated-dose rt-PA with intravenous heparin; (4) combination of streptokinase and conventionally dosed rt-PA with intravenous heparin
Study: 3207350
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice per day
Study: 3207350
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg in a single dose at night
Study: 28644348
Drug: 1-factor partial
Normalized name: ROSIN PARTIALLY DIMERIZED GLYCEROL ESTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-factor partial least squares model with L:M as dependent variable
Study: 28644348
Drug: Adjusted models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjusted models for L:M
Study: 21442636
Drug: Pomalidomide therapy
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide therapy
Study: 19789514
Drug: Intravenous 0.5
Normalized name: immune globulin intravenous 0.5 g intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.5 mg/kg ketamine and peritonsillar 0.25% bupivacaine (3-5 ml per tonsil)
Study: 19789514
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline and peritonsillar bupivacaine
Study: 19789514
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and peritonsillar saline solution (placebo)
Study: 16794136
Drug: IV bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV bolus injection of 2 mL/kg of nonionic iodine contrast material (300 mg I/mL) at 4 mL/s
Study: 10678628
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy only (Group B)
Study: 30636490
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 25 mg/kg/8 hours 3 times)
Study: 30636490
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of N-Acetylcysteine (IV: 25 mg/kg bolus and then 75 mg/kg over 24 hours)
Study: 15156070
Drug: Carbatrol (CBR)
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbatrol (CBR) at dosages of 800, 1200, 1600 mg/day
Study: 3290356
Drug: Ketanserin treatment
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin treatment for 5 weeks
Study: 17687099
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment strategies including mucolytic agents, physiotherapy, exercise, antibiotics, nutritional strategies, anti-inflammatory treatments, and vaccinations against common respiratory pathogens.
Study: 2166699
Drug: Pork Insulin
Normalized name: Pork insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork Insulin (PI)
Study: 1643799
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Insulin (HI)
Study: 2166699
Drug: Pork Insulin
Normalized name: Pork insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork Insulin (PI) after 20 min of hypoglycemia
Study: 2166699
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Insulin (HI) after 20 min of hypoglycemia
Study: 31234651
Drug: Alternative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative medicine strategies for diabetes control
Study: 26505288
Drug: Pre-exposure to
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exposure to tempting unhealthy food (e.g. candy)
Study: 20709866
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg, 4 times/day)
Study: 17396059
Drug: Conventional Cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Cigarettes (CC)
Study: 15878496
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate combination (SFC) product (50/250 microg bid via the Diskus inhaler)
Study: 11888872
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (axillary RT and no axillary treatment)
Study: 28594783
Drug: 17α‐hydroxyprogesterone caproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17α‐hydroxyprogesterone caproate (341 mg per week)
Study: 28594783
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg per day)
Study: 12765424
Drug: mepolizumab (SB
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab (SB 240563) anti‐IL‐5 antibody administered three times
Study: 9752908
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection transthecal technique using 3 cc of lignocaine and bupivacaine mixture
Study: 8210390
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose erythromycin therapy (200 mg three times daily)
Study: 3333017
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg stanozolol daily for 12 weeks
Study: 23666681
Drug: NT‐proBNP‐guided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP‐guided therapy
Study: 22282728
Drug: 6.3 mm-long
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3 mm-long implants
Study: 22282728
Drug: 9.3 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.3 mm or longer implants
Study: 1822264
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg/day)
Study: 18443191
Drug: Non-ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACE inhibitor therapy
Study: 17343258
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (2 weeks without treatment)
Study: 14665584
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate ingestion (1 litre of solution containing 0.5 g of sodium citrate/kg body mass two hours before the run)
Study: 6202971
Drug: Atenolol (0.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (0.19 mg/kg)
Study: 7986160
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-blocker)
Study: 20031608
Drug: Atenolol treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol treatment
Study: 6202971
Drug: Practolol treatment
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol treatment
Study: 29313286
Drug: Once-daily single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily single inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) 100 µg/62.5 µg/25 µg
Study: 29313286
Drug: Twice-daily inhaled
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily inhaled corticosteroid/long-acting β2-agonist therapy (budesonide/formoterol) 400 µg/12 µg
Study: 23089047
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride (BZK) gel
Study: 23089047
Drug: Nonoxynol-9 (N-9)
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (N-9) gel
Study: 18713505
Drug: End-of-treatment chest
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment chest radiograph (EOT CXR) showing persistent cavity
Study: 18713505
Drug: End-of-treatment chest
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-of-treatment chest radiograph (EOT CXR) showing resolved cavity
Study: 9236420
Drug: Xemilofiban 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xemilofiban 35 mg orally before and 20 to 25 mg TID for 30 days after angioplasty
Study: 12824459
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg per day)
Study: 11584088
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation
Study: 22888611
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation
Study: 1905836
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum globulin (ISG) 2 ml i.m. at premedication and 2 ml i.m. on postoperative day 3
Study: 1593145
Drug: Bupivacaine hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine hydrochloride (one ml) and buprenorphine 300 micrograms in combination (Group B)
Study: 20350428
Drug: Probiotics treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics treatment group (Clostridium butyricum powder, 250 mg, twice daily up to discharge)
Study: 20350428
Drug: Probiotics treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics treatment group
Study: 17604473
Drug: Clofibate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (100 mg/kg single oral dose)
Study: 10843152
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg
Study: 12425125
Drug: Rocuronium, 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium, 0.03 mg/kg
Study: 1736336
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily for 2 weeks
Study: 3512351
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily for 4 weeks
Study: 2011700
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine once daily for 4 weeks
Study: 6399407
Drug: Tinidazole (2-gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2-gram single dose)
Study: 23115322
Drug: Beta-blocker dose
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker dose
Study: 26212489
Drug: EE/DRSP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (20 μg EE/3 mg DRSP)
Study: 17645506
Drug: Epoetin 150
Normalized name: METHOXY PEG-EPOETIN 150MCG/0.3ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin 150 IU/kg three times weekly
Study: 11310081
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during the examination
Study: 8707479
Drug: Placebo EMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo EMF treatment
Study: 22644797
Drug: 5-mg axitinib
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg axitinib Form XLI FCIR tablets with moderate-fat, standard-calorie meal
Study: 22644797
Drug: 5-mg axitinib
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg axitinib Form XLI FCIR tablets
Study: 20196093
Drug: Recruitment strategies
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment strategies including relationship-building, raffles, and screening survey administration
Study: 11349741
Drug: Intravenous fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fludarabine
Study: 8548235
Drug: Preoperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative total parenteral nutrition (TPN)
Study: 28924473
Drug: Chlorhexidine-alcohol combination
Normalized name: chlorhexidine / isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-alcohol combination (product B) applied for 180 s
Study: 23483223
Drug: H-FABP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-FABP levels in SCI patients (paraplegia group: 18.5 ± 11.4 ng/ml; tetraplegia group: 16.3 ± 9.1 ng/ml)
Study: 23483223
Drug: H-FABP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-FABP levels in complete SCI patients with lesions above T6 (24.21 ± 10.1 ng/ml)
Study: 23483223
Drug: H-FABP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-FABP levels in SCI patients with metabolic syndrome (MetS) (25.8 ± 11.6 ng/ml)
Study: 19451819
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progesterone replacement therapy
Study: 8390232
Drug: Washout group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout group (post-treatment follow-up)
Study: 25219563
Drug: ProQuad® (MMRV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad® (MMRV) first dose
Study: 25219563
Drug: ProQuad® (MMRV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProQuad® (MMRV) second dose
Study: 9444543
Drug: Placebo (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8-week treatment)
Study: 11020749
Drug: Caudal S(+)-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal S(+)-ketamine 1 mg/kg
Study: 11020749
Drug: Intramuscular S(+)-ketamine
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular S(+)-ketamine 1 mg/kg
Study: 30395812
Drug: RPC4046 180
Normalized name: IMMUNOGLOBULIN G1(240-ALANINE, 241-ALANINE), ANTI-(HUMAN INTERLEUKIN 13) (HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .GAMMA.-1), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .KAPPA.-1, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPC4046 180 mg
Study: 30395812
Drug: RPC4046 360
Normalized name: IMMUNOGLOBULIN G1(240-ALANINE, 241-ALANINE), ANTI-(HUMAN INTERLEUKIN 13) (HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .GAMMA.-1), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RPC4046 .KAPPA.-1, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPC4046 360 mg
Study: 18363424
Drug: Multi-family psychoeducational
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-family psychoeducational group + pharmacotherapy
Study: 15555694
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone
Study: 9177961
Drug: Five-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day treatment with cefprozil
Study: 9177961
Drug: Ten-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day treatment with cefprozil (in patients with three or more previous episodes)
Study: 3100466
Drug: Stanozolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol (10 mg/day)
Study: 27026642
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisone orally followed by 2 doses of intravenous hydrocortisone, each 8 hours apart
Study: 25049134
Drug: Exendin‐[9‐39] (Ex‐9)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin‐[9‐39] (Ex‐9) infusion (600‐750 pmol/kg/min)
Study: 20413036
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) infusion
Study: 22554716
Drug: Cystagon (immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystagon (immediate-release cysteamine bitartrate) taken every 6 hours
Study: 22554716
Drug: RP103 (delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP103 (delayed-release cysteamine bitartrate)
Study: 14970004
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) infusion
Study: 10473874
Drug: GPIIb/IIIa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPIIb/IIIa inhibitors
Study: 2273204
Drug: Estrogen/progesterone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/progesterone therapy
Study: 7375871
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 50 mg indomethacin
Study: 7375871
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg q.i.d. for 8 days
Study: 30004624
Drug: Intraoperative remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative remifentanil infusion (0.2 μg/kg/min) discontinued upon surgery completion
Study: 12199627
Drug: IFL combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFL combination (fluorouracil [5‐FU], leucovorin, and irinotecan [CPT‐11, Camptosar])
Study: 9569999
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin, diclofenac, naproxen, indomethacin, and ibuprofen
Study: 3195729
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg EM with 0.125% bupivacaine
Study: 23227695
Drug: Shu-needle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shu-needle therapy combined with ozone injection of low concentration
Study: 23227695
Drug: Conventional acupotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupotomy therapy combined with ozone injection of low concentration
Study: 19036146
Drug: Transarterial chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial chemoembolization plus sorafenib 400 mg bid
Study: 16096175
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (Estalis)
Study: 16096175
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (Kliogest)
Study: 25222574
Drug: Intra-articular magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular magnesium sulphate (100 mg/mL, 10 mL)
Study: 19800815
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (10 mL)
Study: 15522005
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment for 3 days
Study: 15522005
Drug: Rifaximin treatment
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin treatment
Study: 10328567
Drug: Intranasal diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal diazepam (2 mg)
Study: 10328567
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (2 mg)
Study: 22427020
Drug: Caffeine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2 mg/kg)
Study: 11514302
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg/kg)
Study: 637293
Drug: Two vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vial formulation of etomidate (30 mg etomidate sulphate in 20 ml phosphate buffered solution)
Study: 637293
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of etomidate (5ml ampoules containing 2% etomidate base in polyethylene glycol 1000)
Study: 637293
Drug: Two vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vial formulation of etomidate
Study: 31596411
Drug: Infant stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant stimulation therapy (auditory, tactile, visual and vestibular)
Study: 17272285
Drug: Community pharmacy-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacy-led medicines management intervention
Study: 14757388
Drug: L-alanyl-L-glutamine-supplemented TPN
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl-L-glutamine-supplemented TPN (0.40 g/kg/d)
Study: 9768932
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (group TA; n = 14)
Study: 804952
Drug: Tolamolol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol 200 mg thrice daily
Study: 804952
Drug: Tolamolol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolamolol (both doses)
Study: 28202067
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in addition to standard treatment (N=61 for each study group)